» Articles » PMID: 24920856

Functional Connectivity in the Basal Ganglia Network Differentiates PD Patients from Controls

Overview
Journal Neurology
Specialty Neurology
Date 2014 Jun 13
PMID 24920856
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine functional connectivity within the basal ganglia network (BGN) in a group of cognitively normal patients with early Parkinson disease (PD) on and off medication compared to age- and sex-matched healthy controls (HC), and to validate the findings in a separate cohort of participants with PD.

Methods: Participants were scanned with resting-state fMRI (RS-fMRI) at 3T field strength. Resting-state networks were isolated using independent component analysis. A BGN template was derived from 80 elderly HC participants. BGN maps were compared between 19 patients with PD on and off medication in the discovery group and 19 age- and sex-matched controls to identify a threshold for optimal group separation. The threshold was applied to 13 patients with PD (including 5 drug-naive) in the validation group to establish reproducibility of findings.

Results: Participants with PD showed reduced functional connectivity with the BGN in a wide range of areas. Administration of medication significantly improved connectivity. Average BGN connectivity differentiated participants with PD from controls with 100% sensitivity and 89.5% specificity. The connectivity threshold was tested on the validation cohort and achieved 85% accuracy.

Conclusions: We demonstrate that resting functional connectivity, measured with MRI using an observer-independent method, is reproducibly reduced in the BGN in cognitively intact patients with PD, and increases upon administration of dopaminergic medication. Our results hold promise for RS-fMRI connectivity as a biomarker in early PD.

Classification Of Evidence: This study provides Class III evidence that average connectivity in the BGN as measured by RS-fMRI distinguishes patients with PD from age- and sex-matched controls.

Citing Articles

Effects of four-week intranasal oxytocin administration on large-scale brain networks in older adults.

Liu P, Lin T, Fischer H, Feifel D, Ebner N Neuropharmacology. 2024; 260():110130.

PMID: 39182569 PMC: 11752694. DOI: 10.1016/j.neuropharm.2024.110130.


Why so slow? Models of parkinsonian bradykinesia.

Williams D Nat Rev Neurosci. 2024; 25(8):573-586.

PMID: 38937655 DOI: 10.1038/s41583-024-00830-0.


Brain-wide functional connectome analysis of 40,000 individuals reveals brain networks that show aging effects in older adults.

Pan Y, Bi C, Kochunov P, Shardell M, Smith J, McCoy R bioRxiv. 2024; .

PMID: 38798606 PMC: 11118564. DOI: 10.1101/2024.05.17.594743.


How should we be using biomarkers in trials of disease modification in Parkinson's disease?.

Vijiaratnam N, Foltynie T Brain. 2023; 146(12):4845-4869.

PMID: 37536279 PMC: 10690028. DOI: 10.1093/brain/awad265.


Unleashing the potential of dance: a neuroplasticity-based approach bridging from older adults to Parkinson's disease patients.

Meulenberg C, Rehfeld K, Jovanovic S, Marusic U Front Aging Neurosci. 2023; 15:1188855.

PMID: 37434737 PMC: 10331838. DOI: 10.3389/fnagi.2023.1188855.


References
1.
Laird A, Fox P, Eickhoff S, Turner J, Ray K, McKay D . Behavioral interpretations of intrinsic connectivity networks. J Cogn Neurosci. 2011; 23(12):4022-37. PMC: 3690655. DOI: 10.1162/jocn_a_00077. View

2.
Robinson S, Basso G, Soldati N, Sailer U, Jovicich J, Bruzzone L . A resting state network in the motor control circuit of the basal ganglia. BMC Neurosci. 2009; 10:137. PMC: 2785820. DOI: 10.1186/1471-2202-10-137. View

3.
Cole D, Beckmann C, Oei N, Both S, van Gerven J, Rombouts S . Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity. Neuroimage. 2013; 78:59-67. DOI: 10.1016/j.neuroimage.2013.04.034. View

4.
Esposito F, Tessitore A, Giordano A, De Micco R, Paccone A, Conforti R . Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. Brain. 2013; 136(Pt 3):710-25. DOI: 10.1093/brain/awt007. View

5.
Goetz C, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins G . Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2006; 22(1):41-7. DOI: 10.1002/mds.21198. View